Related Experiment Video
Updated: May 22, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
Published on: January 19, 2010
Aminosalicylates.
1Medizinische Klinik 2, Klinikum St. Marien, Amberg, Deutschland. gross.volker@klinikum-amberg.de
Digestive Diseases (Basel, Switzerland)
|May 11, 2012
Summary
Mesalazine shows promise in managing symptomatic diverticular disease and preventing diverticulitis recurrence. Further research is ongoing to confirm its efficacy in various treatment scenarios.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Symptomatic diverticular disease is common in Western countries.
- Limited medical interventions exist for symptomatic diverticular disease beyond antibiotics for acute diverticulitis.
- Mesalazine's anti-inflammatory properties suggest potential therapeutic benefits.
Purpose of the Study:
- To evaluate the role of mesalazine in preventing diverticulitis recurrence.
- To assess mesalazine's efficacy in improving symptoms of symptomatic uncomplicated diverticular disease.
- To investigate mesalazine's effectiveness in segmental colitis associated with diverticulosis.
Main Methods:
- Review of randomized open studies on mesalazine for diverticulitis recurrence.
- Analysis of ongoing randomized placebo-controlled trials for diverticulitis prevention.
- Examination of randomized uncontrolled studies assessing mesalazine for symptomatic diverticular disease.
- Review of case reports on mesalazine for segmental colitis associated with diverticulosis.
Main Results:
- Randomized open studies suggest mesalazine may prevent diverticulitis recurrences.
- Several ongoing trials are expected to clarify mesalazine's role in diverticulitis prevention.
- Some studies indicate mesalazine improves symptoms in uncomplicated diverticular disease.
- Case reports suggest mesalazine is effective for segmental colitis associated with diverticulosis.
Conclusions:
- Mesalazine demonstrates potential in preventing diverticulitis recurrence and managing symptoms.
- Further high-quality randomized controlled trials are needed to establish mesalazine's definitive role.
- Mesalazine may be a viable option for specific diverticular disease manifestations.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...